IFITM3 and acute myeloid leukemia: Consistent with literature reports that showed IFITM3 as a prognostic marker associated with progression of head and neck squamous cell carcinoma [46] and acute myeloid leukemia [47], our study also illustrated that overexpression of IFITM3 was closely correlated with advanced pathological stages in GC.